1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Realcan Pharmaceutical Group Co., Ltd. Class A

Realcan Pharmaceutical Group Co., Ltd. Class A

SSZSE:002589
2.90
CNY
+0.05
(+1.75%)
0.04EPS
191.38P/E
3.70BMarket Cap
Realcan Pharmaceutical Group Co., Ltd. Class A
SZSE:002589
(Shenzhen Stock Exchange)

Recent

price

2.90

P/E

ratio

191.38

div

yld

2.57%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.45
4.26
5.36
6.73
7.86
7.91
11.55
15.48
22.87
23.56
18.76
14.45
8.34
5.34
6.48
4.54
4.78
Revenue per Share
0.1
0.11
0.13
0.16
0.18
0.19
0.44
0.67
0.52
-0.62
0.18
0.09
-1.24
0.01
0.01
0.01
0.01
Basic EPS, GAAP
0.05
-0.67
-0.33
-0.49
-0.35
-0.47
-1.54
-1.87
-0.55
0.77
-0.16
-0.01
0.24
-0.14
0.04
-0.01
- -
Free Cash Flow per Basic Share
0.02
0.03
0.05
0.08
0.08
0.08
0.08
0.15
0.35
0.33
0.24
0.22
0.1
0.13
0.16
0.11
0.07
Dividend per Share
0.46
0.94
1.06
1.63
1.79
2.5
4.57
5.19
5.64
4.78
4.96
5.03
3.59
3.62
3.69
3.52
3.53
Book Value per Share
0.4
0.89
0.99
1.54
1.66
2.08
3.52
2.61
3.33
3.79
4.21
4.29
3.08
3.16
3.28
3.07
3.09
Tangible Book Value per Share
642
751
863
880
991
1,233
1,352
1,505
1,483
1,496
1,452
1,458
1,477
1,505
1,229
1,607
1,483
Basic Weighted Avg Shares
2,213
3,195
4,622
5,926
7,786
9,750
15,619
23,294
33,919
35,259
27,234
21,060
12,311
8,034
7,967
7,296
7,091
Sales/Revenue/Turnover
4.84
4.56
4.54
4.61
4.19
4.31
6.61
8.18
8.38
7.36
5.93
4.91
0.55
-0.81
0.82
0.93
0.63
Operating Margin (%)
5
6
8
12
24
43
79
147
234
275
291
319
284
220
199
179
- -
Depreciation Expense
62
84
111
144
181
236
591
1,008
771
-928
261
131
-1,831
20
12
16
19
Net Income, GAAP
25.3
25.27
25.14
25.46
24.82
23.65
23.12
24.41
35.08
524.89
31.75
17.85
- -
- -
1.89
- -
- -
Effective Tax Rate (%)
2.81
2.63
2.39
2.42
2.32
2.42
3.78
4.33
2.27
-2.63
0.96
0.62
-14.87
0.25
0.15
0.22
0.27
Profit Margin (%)
202
698
652
1,186
1,196
1,995
4,696
5,461
7,464
7,097
5,383
4,164
351
778
1,140
791
788
Working Capital
- -
- -
- -
- -
- -
- -
- -
1,667
2,132
1,326
24
88
70
262
331
236
217
LT Debt
296
817
916
1,650
1,825
3,404
7,503
9,674
11,338
10,253
10,515
9,693
5,751
5,637
5,709
5,423
5,451
Total Equity
13.11
10.1
8.51
7.12
6.31
5.89
9.28
11.18
7.47
-3.06
3.54
2.43
- -
- -
0.12
- -
- -
Return on Invested Capital (%)
15.04
12.08
10.37
9.42
8.43
7.32
8.15
6.52
3.81
-25.4
1.63
1.97
- -
- -
1.49
- -
- -
Return on Capital (%)
23.44
15.13
12.78
11.27
10.55
9.45
11.73
13.73
9.47
-11.84
3.57
1.74
-28.22
0.37
0.22
0.3
0.35
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,369
4,640
4,961
LT Borrowings
235
398
215
LT Finance Leases
1
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,505
1,505
1,505
Market Capitalization
4,845
4,695
3,702

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,453
10,605
11,023
Cash, Cash Equivalents & STI
3,745
5,050
5,752
Accounts Receivable, Net
3,711
3,813
3,606
Inventories
715
652
631
Total Current Liabilities
8,662
9,656
10,234
Payables & Accruals
- -
- -
- -
ST Debt
4,369
4,640
4,961
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.53%
-10.84%
-5.01%
Free Cash Flow
-268.09%
-508.88%
-126.54%
Net Income, GAAP
-180.63%
-331.08%
30.73%
Sales/Revenue/Turnover
2.79%
-21.64%
-8.42%
Total Cash Common Dividend
17.22%
-8.58%
-12.28%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,019
2,013
2,025
1,910
7,967
2025
1,757
1,787
- -
1,889
7,296
2026
1,707
1,707
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
-0.01
0.01
2025
0.01
- -
- -
- -
0.01
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.03
0.04
0.02
0.16
2025
0.05
0.03
- -
0.01
0.11
2026
0.05
-0.02
- -
- -
- -
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Realcan Pharmaceutical Group Co., Ltd. Realcan Pharmaceutical Group Co., Ltd. (002589.SZ) operates as a comprehensive medical service provider in China, primarily engaged in the distribution of pharmaceuticals, medical devices, and medical consumables to medical institutions nationwide. The company offers an extensive range of products including psychotropic substances, narcotic drugs, antibiotics, innovative drugs, biochemical pharmaceuticals, biological products, chemical drug materials, chemical preparations, traditional Chinese medicine materials, Chinese medicine tablets, Chinese patent medicines, and granules; it also provides services across segments such as drug and device distribution, in vitro diagnostics covering laboratory biochemistry, immunity, and clinical examination, digital medical solutions including one-stop health management platforms, pharmaceutical logistics with third-party services, academic promotion, hospital management consulting, medical diagnosis, equipment research and development, production, and financial technology. Its sales network spans 31 provinces and cities, directly serving nearly 60,000 medical institutions and supporting leading domestic and foreign manufacturers. Founded in 2004 and headquartered in Yantai, Shandong Province, the company listed on the Shenzhen Stock Exchange in June 2011 and changed its name from Realcan Pharmaceutical Co., Ltd. to its current form in December 2018. Recent developments include an ongoing share repurchase program initiated in 2024, with tranches completed through November 2025 repurchasing over 1% of shares for approximately CNY 75 million to stabilize market confidence; in June 2024, it formed a strategic joint venture with Meiyitain Biotechnology (Wuhan) Co., Ltd., Shandong Ruikang Microecology Engineering Co., Ltd., to develop fecal microbiota transplantation technologies, establishing production centers and clinical services for conditions like autism; additionally, it continues expansions in digital transformation projects, such as cloud computing initiatives and selection for provincial service industry development funds in 2023-2024, alongside school-enterprise partnerships like the April 2024 collaboration with Yantai Preschool Normal College for training bases.